This section shows a general overview of information for the selected study (COSU identifier) or publication (COSP identifier). Studies may have been performed by the Sanger Institute Cancer Genome Project, or imported from the ICGC/TCGA. You can see more information on the help pages.
- A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
- Paper ID
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Research Initiative for ALK-Related Malignancies, Cambridge, United Kingdom. Electronic address: email@example.com.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019;14(11):e257-e259
PMID: 31668326 (view at PubMed or Europe PMC)
- Paper Status
- Genes Analysed
- Mutated Samples
- Total No. of Samples